scholarly journals A Comparative study on the cost effectiveness of intervention of noncommunicable disease in south Darfur 2017

2021 ◽  
Vol 2 (1) ◽  
pp. 019-025
Author(s):  
Yousif Adam Hussien Noreldin ◽  
Ekram Adam Eldoom
Keyword(s):  
Health Insurance ◽  
Cost Effectiveness ◽  
National Health Insurance ◽  
National Health ◽  
Noncommunicable Disease ◽  
Noncommunicable Diseases ◽  
Insurance Fund ◽  
Health Insurance Fund ◽  
National Health Insurance Fund ◽  
The Cost

Background: This study conducted to assess the cost effectiveness of common interventions used to control Noncommunicable diseases in south Darfur. Noncommunicable diseases are becoming an increasing public health concern due to their economic significance, and their great impact on the ability of affected individuals to contribute to their communities, and the high burden it represents on the health system. Objectives: To evaluate the role of health insurance fund in controlling Noncommunicable diseases. To assess cost effectiveness of the management of Noncommunicable disease within the National Health insurance fund system. Methods: This study is designed to use secondary data from the national health insurance fund in south Darfur, comparing the cost for the management of 3 selected Noncommunicable diseases (Hypertension, Heart disease, and Diabetes). I have reviewed the entire data of the year 2017 and compared the cost effectiveness of the currently used interventions against health promotion and coordinated approach within the national health insurance fund. Results: The 3 selected disease (Heart Disease, Hypertension and Diabetes) has significant burden on the health system, both financially and operationally. The NHIF concentrates on the management of Noncommunicable diseases without paying due attention to the importance of prevention strategies such as health promotion, community based integrated management of NCDs, and coordination among other sectors. Conclusion: To effectively reduce the financial burden of Noncommunicable disease; the NHIF needs to concentrate on prevention of Noncommunicable diseases through extensive health promotion campaigns, promotion of healthy lifestyle, and coordinated approach to controlling Noncommunicable disease.

scholarly journals Availability and reimbursement of biological products for severe asthma in Bulgaria

2020 ◽  
Vol 8 ◽  
pp. 205031212095106
Author(s):  
Petya Milushewa ◽  
Miglena Doneva ◽  
Guenka Petrova
Keyword(s):  
Health Insurance ◽  
Severe Asthma ◽  
National Health Insurance ◽  
National Health ◽  
Biological Therapy ◽  
Insurance Fund ◽  
Health Insurance Fund ◽  
National Health Insurance Fund ◽  
Biological Products ◽  
The Cost

Objectives: This study aims to analyze the reimbursement and cost of biological therapy for severe asthma in Bulgaria during 2014–2019 from the perspective of the National Health Insurance Fund. Methods: It is a retrospective, Marco-costing, top-down study of the expenditures for biological products for severe asthma. The changes in the cost paid by the National Health Insurance Fund per year, per product, and per patient during 2015–2020 were systematized and calculated. The utilization of biologicals was analyzed by calculating the defined daily dose/1000inh/day. Three databases were searched—the European Medicines Agency for the date of marketing authorization of biological products, National Council of Prices and Reimbursement for the date of their respective inclusion in the positive drug list, and National Health Insurance Fund about the number of patients with asthma, reimbursed sum for all asthma patients, and number of packages sold of biological products. Results: At the end of 2019, five international non-proprietary names of biologicals with indication for severe asthma had received European marketing authorization, and three of them were included in the Bulgarian positive drug list—omalizumab, mepolizumab, and benralizumab with a 75% reimbursement. Upon their introduction into the positive drug list, the reimbursed expenditures for asthma therapy started to increase from 27 million in 2014 to 33 million BGN in 2019 (€13.5–€16.5 million). The cost of therapy with biologicals rose from 16% to 24% of all anti-asthmatic medicines budget. The National Health Insurance Fund database reported that between 47,000 and 52,000 of patients with asthma, 466 are on biological therapy. The yearly cost of one asthma patient ranges between 512 and 615 BGN (€258–€307), and the yearly per-patient cost of severe asthma is 16,666 BGN (appr. €8333). Total utilization in defined daily dose/1000inh/day increases from 0.0199 to 0.0383 from 2015 to 2019. Conclusion: The access to biological therapy through the reimbursement system has improved during the last 3 years. The cost of therapy is posing a high burden on the National Health Insurance Fund and on the patients and is expected to increase due to the small number of patients on biological therapy currently in comparison to all reimbursed asthmatics.

Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial

2014 ◽  
Vol 155 (17) ◽  
pp. 669-675
Author(s):  
Gábor Simonyi
Keyword(s):  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Ldl Cholesterol ◽  
Patient Adherence ◽  
Lipid Lowering ◽  
Insurance Fund ◽  
Lipid Lowering Therapy ◽  
Health Insurance Fund ◽  
National Health Insurance Fund

Introduction: Dyslipidemia is a well-known cardiovascular risk factor. To achieve lipid targets patient adherence is a particularly important issue. Aim: To assess adherence and persistence to statin therapy in patients with atherosclerotic disease who participated in the MULTI Goal Attainment Problem 2013 (MULTI GAP 2013) study. Patient adherence was assessed using estimation by the physicians in charge and analysis of pick up rate of prescribed statins in 319 patients based on data of National Health Insurance Fund Administration of Hungary. Method: In the MULTI GAP 2013 study, data from standard and structured questionnaires of 1519 patients were processed. Serum lipid values of patients treated by different healthcare professionals (general practitioners, cardiologists, diabetologists, neurologists, and internists), treatment adherence of patients assessed by doctors and treatment adherence based on data of National Health Insurance Fund Administration of Hungary were analysed. Satisfaction of doctors with results of statin therapy and the relationship between the level of adherence and serum lipid values were also evaluated. Results: Considering the last seven years of survey data, the use of more effective statins became more prevalent with an about 70% increase of prescriptions of atorvastatin and rosuvastatin from 49% to 83%. Patients with LDL-cholesterol level below 2.5 mmol/l had 8 prescriptions per year. In contrast, patients who had LDL-cholesterol levels above 2.5 mmol/l had only 5.3–6.3 prescriptions per year. Patients who picked up their statins 10–12 or 7–9 times per year had significantly lower LDL-cholesterol level than those who had no or 1–3 pick up. The 100% persistence assessed by doctors was significantly lower (74%) based on data from the National Health Insurance Fund Administration of Hungary. About half of the patients were considered to display 100% adherence to lipid-lowering therapy by their doctors, while data from the National Health Insurance Fund Administration of Hungary showed only 36%. In patients with better adherence (90–100%) LDL-cholesterol levels below 2.5 mmol/l were more frequent (59.5%) compared to those with worse adherence. Satisfaction of doctors with lipid targets achieved was 69–80% in patients with total cholesterol between 4.5 and 6 mmol/l, and satisfaction with higher cholesterol values was also high (53–54%). Conclusions: The results show that doctors may overestimate patient adherence to lipid-lowering treatment. Based on data from the National Health Insurance Fund Administration of Hungary, satisfaction of doctors with high lipid level appears to be high. There is a need to optimize not only patient adherence, but adherence of doctors to lipid guidelines too.

scholarly journals A cukorbeteg-ellátás mutatóinak alakulása Magyarországon 2001–2014 között. Az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének célja és módszertana

2016 ◽  
Vol 157 (32) ◽  
pp. 1259-1265 ◽  
Author(s):  
György Jermendy ◽  
Péter Kempler ◽  
Zsolt Abonyi-Tóth ◽  
György Rokszin ◽  
István Wittmann
Keyword(s):  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Insurance Fund ◽  
Health Insurance Fund ◽  
Database Analysis ◽  
National Health Insurance Fund ◽  
Antidiabetic Treatment ◽  
Outpatient Departments ◽  
Central Database

In the last couple of years, database analyses have become increasingly popular among clinical-epidemiological investigations. In Hungary, the National Health Insurance Fund serves as central database of all medical attendances in state departments and purchases of drug prescriptions in pharmacies. Data from in- and outpatient departments as well as those from pharmacies are regularly collected in this database which is public and accessible on request. The aim of this retrospective study was to investigate the database of the National Health Insurance Fund in order to analyze the diabetes-associated morbidity and mortality in the period of years 2001–2014. Moreover, data of therapeutic costs, features of hospitalizations and practice of antidiabetic treatment were examined. The authors report now on the method of the database analysis. It is to be hoped that the upcoming results of this investigation will add some new data to recent knowledge about diabetes care in Hungary. Orv. Hetil., 2016, 157(32), 1259–1265.

Sign in / Sign up

Export Citation Format

Share Document